Amy Lin, MD

TitleAssociate Professor
SchoolUCSF School of Medicine
Address550 16th Street
San Francisco CA 94158
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Oregon Health Sciences UniversityGraduate certificateCurrentBiomedical and Health Informatics
    University of California, San FranciscoFellowship2006Oncology: Genitourinary Medical Oncology
    New York Presbyterian Hospital CornellResidency2002Internal Medicine
    University of Chicago PritzkerM.D.1999School of Medicine
    Harvard UniversityA.B. 1993Biology
    Collapse Awards and Honors
    University of California San Francisco2015Pinnacle "Voice of the Patient" Team Award
    Marin Magazine2015  - 2017[415] Top Doctors
    Cancer and Leukemia Group B (CALGB)2007Young Investigator Award
    American Society of Clinical Oncology2005Young Investigator Award
    American Society of Clinical Oncology2005 Prostate Cancer Symposium Merit Award
    AACR/ASCO2004Clinical Cancer Research Workshop
    University of Chicago1998Calvin Fentress Research Fellowship Award
    Harvard University1992Elizabeth Agassiz Award
    Harvard University1991John Harvard Scholarship for Academic Excellence
    Harvard University1990Harvard College Scholarship

    Collapse Overview 
    Collapse Overview
    Amy M Lin is a genitourinary medical oncologist who joined the UCSF faculty in 2005. Dr. Lin works with a multidisciplinary team of medical oncologists, radiation oncologists, and urologic surgical oncologists at UCSF and the San Francisco Veterans Administration Medical Center where she sees all types of genitourinary malignancies including prostate, kidney, bladder and testicular cancer. Dr. Lin is also a member of the core UCSF Cancer Immunotherapy Clinic team and cares for patients with all cancer types on novel immunotherapy studies. She is currently an Associate Professor of Medicine and Urology.

    Dr. Lin’s focus is on improving clinical care workflows to optimize health care delivery. She is interested in how health care technology can enhance certain aspects of patient care and believes that increasing the quality of health care data collection, integration of multi-source patient health care data, and data interoperability are key to these efforts. Dr. Lin has been an active subject matter expert on electronic health record (EHR) clinical workflows within the Cancer Center. She is also a member of the American Society of Clinical Oncology (ASCO) CancerLinQ Research and Publications Committee which is a large scale national effort to collect and analyze real world (non-clinical trial) oncology patient data and outcomes.

    Collapse ORNG Applications 
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Friedlander TW, Graff JN, Zejnullahu K, Anantharaman A, Zhang L, Paz R, Premasekharan G, Russell C, Huang Y, Kim W, Aggarwal RR, Lin A, Fong L, Alumkal JJ, Beer TM, Sharifi N, Alyamani M, Dittamore R, Small EJ, Paris PL, Ryan CJ. High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer. Clin Genitourin Cancer. 2017 Jun 03. PMID: 28655452.
      View in: PubMed
    2. Wei XX, Hsieh AC, Kim W, Friedlander T, Lin A, Louttit M, Ryan CJ. A Phase I Study of Abiraterone Acetate Combined with BEZ235, a Dual PI3K/mTOR Inhibitor, in Metastatic Castration Resistant Prostate Cancer. Oncologist. 2017 May; 22(5):503-e43. PMID: 28314838.
      View in: PubMed
    3. Aggarwal R, Bryce A, Ryan CJ, Harzstark A, Derleth C, Kim W, Friedlander T, Lin A, Rodvelt-Bagchi T, Dhawan M, Zhang L, Lee M, Siebeneck E, Hough J, Small EJ. A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: A department of defense prostate cancer clinical trials consortium study. Urol Oncol. 2017 Apr; 35(4):149.e7-149.e13. PMID: 28161323.
      View in: PubMed
    4. Wei XX, Chan S, Kwek S, Lewis J, Dao V, Zhang L, Cooperberg MR, Ryan CJ, Lin A, Friedlander TW, Rini B, Kane C, Simko JP, Carroll PR, Small EJ, Fong L. Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate Cancer. Cancer Immunol Res. 2016 Nov; 4(11):948-958. PMID: 27688020.
      View in: PubMed
    5. Kwek SS, Lewis J, Zhang L, Weinberg V, Greaney SK, Harzstark AL, Lin A, Ryan CJ, Small EJ, Fong L. Preexisting Levels of CD4 T Cells Expressing PD-1 Are Related to Overall Survival in Prostate Cancer Patients Treated with Ipilimumab. Cancer Immunol Res. 2015 Sep; 3(9):1008-16. PMID: 25968455; PMCID: PMC4561203.
    6. Aggarwal RR, Beer TM, Weinberg VK, Higano C, Taplin ME, Ryan CJ, Lin A, Alumkal J, Graff JN, Nordquist LT, Herrera I, Small EJ. Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSF. Clin Genitourin Cancer. 2015 Jun; 13(3):e191-8. PMID: 25557266.
      View in: PubMed
    7. Kim W, Zhang L, Wilton JH, Fetterly G, Mohler JL, Weinberg V, Morse A, Szmulewitz RZ, Friedlander TW, Fong L, Lin A, Harzstark AL, Molina A, Small EJ, Ryan CJ. Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate cancer and the predictive value of circulating androgens. Clin Cancer Res. 2014 Dec 15; 20(24):6269-76. PMID: 25336698; PMCID: PMC4277885.
    8. Friedlander TW, Weinberg VK, Huang Y, Mi JT, Formaker CG, Small EJ, Harzstark AL, Lin A, Fong L, Ryan CJ. A phase II study of insulin-like growth factor receptor inhibition with nordihydroguaiaretic acid in men with non-metastatic hormone-sensitive prostate cancer. Oncol Rep. 2012 Jan; 27(1):3-9. PMID: 21971890.
      View in: PubMed
    9. Harzstark AL, Small EJ, Weinberg VK, Sun J, Ryan CJ, Lin A, Fong L, Brocks DR, Rosenberg JE. A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma. Cancer. 2011 Sep 15; 117(18):4194-200. PMID: 21387258.
      View in: PubMed
    10. Chow H, Jung A, Talbott J, Lin A, Daud AI, Coakley FV. Tumor fistulization associated with targeted therapy: computed tomographic findings and clinical consequences. J Comput Assist Tomogr. 2011 Jan-Feb; 35(1):86-90. PMID: 21245693; PMCID: PMC3675219.
    11. Friedlander TW, Weinberg VK, Small EJ, Sharib J, Harzstark AL, Lin A, Fong L, Ryan CJ. Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II study. Urol Oncol. 2012 Jul-Aug; 30(4):408-14. PMID: 20884247.
      View in: PubMed
    12. Fong L, Kwek SS, O'Brien S, Kavanagh B, McNeel DG, Weinberg V, Lin A, Rosenberg J, Ryan CJ, Rini BI, Small EJ. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res. 2009 Jan 15; 69(2):609-15. PMID: 19147575.
      View in: PubMed
    13. Lin A, Small EJ. Prostate cancer update: 2007. Curr Opin Oncol. 2008 May; 20(3):294-9. PMID: 18391629.
      View in: PubMed
    14. Lin A, Small EJ. Management of hormone refractory prostate cancer. Curr Opin Support Palliat Care. 2007 Oct; 1(3):187-91. PMID: 18685361.
      View in: PubMed
    15. Lin A, Rini BI, Derynck MK, Weinberg V, Park M, Ryan CJ, Rosenberg JE, Bubley G, Small EJ. A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer. Clin Genitourin Cancer. 2007 Jun; 5(5):323-8. PMID: 17645829.
      View in: PubMed
    16. Lin A, Small EJ. Prostate cancer update: 2006. Curr Opin Oncol. 2007 May; 19(3):229-33. PMID: 17414641.
      View in: PubMed
    17. Lin A, Ryan CJ, Small EJ. Intermittent chemotherapy for metastatic hormone refractory prostate cancer. Crit Rev Oncol Hematol. 2007 Mar; 61(3):243-54. PMID: 17161610.
      View in: PubMed
    18. Lin A, Rini BI, Weinberg V, Fong K, Ryan CJ, Rosenberg JE, Fong L, Small EJ. A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy. BJU Int. 2006 Oct; 98(4):763-9. PMID: 16796694.
      View in: PubMed
    19. Lin A, Hershberg RM, Small EJ. Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells. Urol Oncol. 2006 Sep-Oct; 24(5):434-41. PMID: 16962496.
      View in: PubMed
    20. Ryan CJ, Lin A, Small EJ. Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: history and rationale. Urol Oncol. 2006 May-Jun; 24(3):250-3. PMID: 16678059.
      View in: PubMed
    21. Lin A, Rini BI, Small EJ. Clinical trials in patients with biochemically relapsed prostate cancer. BJU Int. 2006 May; 97(5):905-10. PMID: 16643469.
      View in: PubMed
    Back to TOP